DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese

Information source: Tomidahama Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Phase: N/A

Status: Recruiting

Sponsored by: Tomidahama Hospital

Official(s) and/or principal investigator(s):
Rui Niimi, MD, PhD, Study Director, Affiliation: Tomidahama Hospital

Overall contact:
Rui Niimi, MD, PhD, Phone: (81)-59-365-0023, Email: furikakefuri@hotmail.co.jp

Summary

In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.

Clinical Details

Official title: Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Clinical results of bisphosphonate vs. denosmab following daily teriparatide treatment

Detailed description: Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (< young adult mean 65%). Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants

Eligibility

Minimum age: 45 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- severe osteoporotic patients

Exclusion Criteria:

- cancer, hypercalcemia, etc (i. e. patients who could not use bisphosphonate, denosmab,

teriparatide)

Locations and Contacts

Rui Niimi, MD, PhD, Phone: (81)-59-365-0023, Email: furikakefuri@hotmail.co.jp

Tomidahama Hospital, Yokkaichi, Mie 510-8008, Japan; Recruiting
Rui Niimi, MD, PhD, Phone: (81)-59-365-0023, Email: furikakefuri@hotmail.co.jp
Rui Niimi, MD, PhD, Principal Investigator
Additional Information

Starting date: November 2013
Last updated: April 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017